TNF and rheumatoid arthritis: Pathomechanistically one could speculate at this stage that an inhibitory effect of Adalimumab on bone turnover might be mediated by a reduction of RANKL which could already be shown in patients with rheumatoid arthritis and anti-TNF-α therapy [25,26].